Deutsche Bank reiterated a Buy rating on Regeneron Pharma (NASDAQ: REGN) and raised its price target to $410.00 (from $375.00).

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Analyst PT Change

Oppenheimer Downgrades Regeneron Pharma (REGN) to PerformFebruary 13, 2014 7:06 AM Roth Keeps Regeneron (REGN) at 'Buy' Following Q4 Numbers, Outlook; VISTA, OUTLOOK Still in FocusFebruary 12, 2014 1:26 PM BofA/Merrill Lynch Reinstated Regeneron Pharma (REGN) at BuyFebruary 12, 2014 6:49 AM Regeneron Pharma (REGN) May Have Upside From Taxes - AnalystFebruary 11, 2014 10:36 AM UPDATE: Regeneron Pharma (REGN) Easily Tops Q4 EPS Views; Guides FY14 EYLEA SalesFebruary 11, 2014 6:32 AM